October 23, 2019
ICON’s buys Symphony Clinical Research
ICON has acquired Symphony Clinical Research, to boost its ability to offer customers hybrid trial solutions and site support services,…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
October 23, 2019
Dr. Reddy’s confirms its voluntary recall of all ranitidine products in the U.S. market, as some samples contain a probable human carcinogen
Dr.Reddy’s has started a recall in USA of its ranitidine, to confirmed contamination with N-Nitrosodimethylamine (NDMA), classified as a probable…
October 23, 2019
Janssen to expand use of Tremfya in treatment of active psoriatic arthritis
Janssen has submitted a type II variation application to European Medicines agency, looking to get approved guselkumab, which could then…
October 23, 2019
Alexion ends third quarter 2019 with 23% increase in total revenues
Alexion finished the third quarter 2019 with total revenues of $1,263.1 million, which represents a 23% increase over 3the same…
October 23, 2019
FDA grants “Breakthrough Device Designation” to CorFlow Therapeutics to expedite clinical development and regulatory review of its CoFI system
The CoFI™ System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a…
October 23, 2019
Hemogenyx Pharmaceuticals in deal to develop humanized mice with a global pharma company
Hemogenyx Pharmaceuticals has signed a research agreement through is subsidiary Immugenyx, to develop humanized mice as a tool for drug development and testing, including with a global pharmaceutical company, whose identity must remain hidden at its request.
October 23, 2019
FDA approves Trikafta to treat cystic fibrosis in patients older than 12
Vertex Pharmaceuticals got approval from the USFDA for Trikafta, for treating cystic fibrosis in patients older than 12
October 23, 2019
Maze Therapeutics appoints City Hill founder to its Board of Directors
SOUTH SAN FRANCISCO–(BUSINESS WIRE)–Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that Jonathan Lim,…
October 22, 2019
Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)
Moderna recieved second rare disease program to receive Fast Track designation with mRNA-3927, which uses the same proprietary LNP formulation as…
October 22, 2019
Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo
Disarm Therapeutics has presented at Neuroscience 2019 that its novel small molecule SARM1 inhibitors reproduce the axonal protection phenotype seen…